Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicohort study of rinatabart sesutecan in advanced non-small cell lung cancer
2025-522107-18-00Phase 2Authorised
- Sponsor
- Genmab
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of rinatabart sesutecan in non-small cell lung cancer (NSCLC), sponsored by Genmab. Primary endpoint: Objective Response Rate. Planned start May 2026; status: authorised.
02
Drugs
rinatabart sesutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522107-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522107-18-00.